- Home
- SPHR vs ARQT Comparison
SPHR vs ARQT Comparison
Compare SPHR & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPHR
- ARQT
- Stock Information
- Founded
- SPHR 2020
- ARQT 2016
- Country
- SPHR United States
- ARQT United States
- Employees
- SPHR N/A
- ARQT N/A
- Industry
- SPHR Services-Misc. Amusement & Recreation
- ARQT Biotechnology: Pharmaceutical Preparations
- Sector
- SPHR Consumer Discretionary
- ARQT Health Care
- Exchange
- SPHR Nasdaq
- ARQT Nasdaq
- Market Cap
- SPHR 2.1B
- ARQT 2.1B
- IPO Year
- SPHR N/A
- ARQT 2020
- Fundamental
- Price
- SPHR $74.47
- ARQT $23.58
- Analyst Decision
- SPHR Buy
- ARQT Strong Buy
- Analyst Count
- SPHR 8
- ARQT 7
- Target Price
- SPHR $63.88
- ARQT $22.17
- AVG Volume (30 Days)
- SPHR 1.0M
- ARQT 2.5M
- Earning Date
- SPHR 11-04-2025
- ARQT 10-28-2025
- Dividend Yield
- SPHR N/A
- ARQT N/A
- EPS Growth
- SPHR N/A
- ARQT N/A
- EPS
- SPHR N/A
- ARQT N/A
- Revenue
- SPHR $1,075,530,000.00
- ARQT $317,929,000.00
- Revenue This Year
- SPHR $10.41
- ARQT $85.27
- Revenue Next Year
- SPHR $9.71
- ARQT $30.70
- P/E Ratio
- SPHR N/A
- ARQT N/A
- Revenue Growth
- SPHR N/A
- ARQT 129.21
- 52 Week Low
- SPHR $23.89
- ARQT $8.90
- 52 Week High
- SPHR $74.50
- ARQT $27.08
- Technical
- Relative Strength Index (RSI)
- SPHR 70.32
- ARQT 57.12
- Support Level
- SPHR $64.00
- ARQT $23.52
- Resistance Level
- SPHR $74.50
- ARQT $25.35
- Average True Range (ATR)
- SPHR 3.40
- ARQT 1.38
- MACD
- SPHR 0.43
- ARQT 0.06
- Stochastic Oscillator
- SPHR 97.02
- ARQT 52.01
About SPHR Sphere Entertainment Co.
Sphere Entertainment Co is a live entertainment and media company. The firm creates, writes, casts, produces, and tours shows and events. The group has two reportable segments which includeSphere and MSG Networks. Sphere is a next-generation entertainment medium, and MSG Networks operates two regional sports and entertainment networks, as well as a direct-to-consumer (DTC) and authenticated streaming product.
About ARQT Arcutis Biotherapeutics Inc.
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.